Skip to content

IAS: Vicriviroc still effective at 48 weeks in treatment-experienced, but relationship with cancer remains uncertain

IAS: Studies present reassuring data on the use of ART in patients on TB treatment

IAS: Botswanan study finds low concentrations of TB drugs common in HIV-positives, predict TB treatment failure

IAS: Skin cancers more common among HIV-positive people, screening recommended

IAS: Nigerian study finds that HIV-positive women more likely to have menstrual problems, low CD4 cell count and low weight are risks

IAS: Randomised comparison concludes d4T more tolerable than AZT in triple nuke PEP regimen

IAS: PrEP and timed intercourse reduces HIV transmission risk associated with natural conception

IAS: Daily aciclovir doesn't reduce HIV risk in HSV-2-infected women - was poor adherence the reason?

IAS: HPV therapeutic vaccine stimulates immune response in people with HIV